Effects of plazomicin injection: A Synthesis of Findings from 4 Studies

  1. Home
  2. Effects of plazomicin injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of plazomicin injection: A Synthesis of Findings from 4 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of plazomicin injection: A Synthesis of Findings from 4 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

ACHN-490 is a novel aminoglycoside that demonstrates promising activity against a range of bacterial pathogens, including those resistant to existing antibiotics. 4 This next-generation aminoglycoside was designed to target key pathogens, particularly gram-negative organisms and those resistant to older antibiotics. 4 Phase 1 studies have shown that ACHN-490 is well-tolerated in healthy subjects. 3 Furthermore, ACHN-490 exhibits linear and dose-proportional pharmacokinetics, with no accumulation observed after repeated dosing over 5 days. 3

The 23-valent unconjugated pneumococcal polysaccharide vaccine (23vP), routinely administered at the age of 65, has limited effectiveness and revaccination induces attenuated antibody responses. 1 While pneumococcal polysaccharide-protein conjugated vaccines (PCV) are highly effective in infants, it is unclear whether they offer any immunological advantages over 23vP in adults. 2

Benefits and Risks

Benefit Summary

ACHN-490 has shown promising activity against a range of bacterial pathogens, including those resistant to existing antibiotics. 4 It is well-tolerated and exhibits favorable pharmacokinetic properties. 3

Risk Summary

ACHN-490 has been found to be safe and well-tolerated in healthy subjects. 3 Adverse events were generally mild to moderate and resolved quickly. 3

Comparison of Studies

Commonalities

All studies investigated the potential of ACHN-490 as a new antibacterial agent. 4 , 3 , 1 , 2

Differences

Research 4 focused on the in vitro activity of ACHN-490 against various bacteria, while research 3 investigated the pharmacokinetic and safety profile of ACHN-490 in healthy subjects. 1 and 2 examined the effectiveness and immune responses of pneumococcal vaccines in different populations.

Consistency and Contradictions in Findings

The findings suggest that ACHN-490 holds promise as a new antibacterial agent with activity against a range of pathogens, including those resistant to existing antibiotics. 4 , 3 Furthermore, the safety profile of ACHN-490 appears favorable in healthy subjects. 3

Implications for Everyday Life

The potential of ACHN-490 to address the growing threat of drug-resistant bacteria is significant. However, further research is needed to confirm its efficacy and safety in clinical settings. 4 , 3

Limitations of Current Research

The studies on ACHN-490 have primarily focused on healthy subjects, so additional research is needed to assess its efficacy and safety in patients with various conditions. 3 Furthermore, the sample sizes of some studies were relatively small, suggesting a need for larger and more comprehensive investigations.

Future Research Directions

Future research should focus on conducting larger clinical trials to assess the efficacy and safety of ACHN-490 in a broader patient population. 4 , 3 Additional studies are also needed to investigate the potential synergistic effects of ACHN-490 with other antibiotics.

Conclusion

ACHN-490 shows promise as a novel antibacterial agent with activity against drug-resistant bacteria. 4 , 3 While the initial findings are encouraging, further research is crucial to validate its efficacy and safety in clinical settings. It is also important to investigate the potential synergistic effects of ACHN-490 with other antibiotics. 4 , 3

Literature analysis of 4 papers
Positive Content
4
Neutral Content
0
Negative Content
0
Article Type
2
0
1
2
4
1.

Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults.

Author: WatsonLorna, WilsonBrenda J, WaughNorman

Reduces mortality
Reduces pneumococcal bacteremia
Reduces pneumonia

Pneumococcal vaccination showed no benefit in industrialised populations other than for pneumococcal bacteraemia. Clear benefit was demonstrated for mortality and all-cause pneumonia in non-industrial populations.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

2.

Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells.

Author: ClutterbuckElizabeth A, LazarusRajeka, YuLy-Mee, BowmanJaclyn, BatemanElizabeth A L, DiggleLinda, AngusBrian, PetoTim E, BeverleyPeter C, MantDavid, PollardAndrew J

Pneumococcal infection prevention

The 23-valent unconjugated pneumococcal polysaccharide vaccine (23vP) is commonly given to adults over 65, but its effectiveness is limited and revaccination leads to weaker antibody responses. It is unclear if pneumococcal polysaccharide-protein conjugated vaccines (PCV), which are highly effective in infants, offer any advantages over 23vP for adults.

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects.

Author: CassRobert T, BrooksCarter D, HavrillaNancy A, TackKenneth J, BorinMarie T, YoungDon, BrussJon B

Anti-bacterial activity
Linear PK
Mild to moderate AE
Rapidly resolved AE

This study investigated the pharmacokinetics (PK), safety, and tolerability of ACHN-490, an aminoglycoside with activity against multidrug-resistant pathogens, in healthy subjects. The study found that ACHN-490 exhibited linear and dose-proportional PK with no evidence of accumulation over multiple doses. The drug was generally safe and well-tolerated, with no significant nephrotoxicity or ototoxicity observed. The findings support the potential of ACHN-490 as a therapeutic option for multidrug-resistant infections.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Combating evolution with intelligent design: the neoglycoside ACHN-490.

Author: ArmstrongEliana S, MillerGeorge H

Antibacterial activity

ACHN-490, the first neoglycoside, shows promising in vitro activity against wild-type and resistant bacteria, suggesting its potential to address the growing need for new antibacterial agents.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.